Showing results (2281-2290 of 2,317) with videos related to
Sort By:
Pageof 232
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.Translational Lung Cancer Research|February 4, 2020
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancerYunpeng Yang, Bin Wu, Linian Huang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.Pageof 232